SavedAdd your journal

Journals / Erciyes Medical Journal / 2021 / Cilt: 43 - Sayı: 5

Is it Worth Using Thrombolytic Therapy in ElderlyPatients with Pulmonary Embolism

Aziz GÜMÜŞ
Songül ÖZYURT
Neslihan ÖZÇELİK
Bilge YILMAZ KARA
Ünal ŞAHİN
Dilek KARADOĞAN
Pages
433–437
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Mortality and complication rates in geriatric patients receiving thrombolytic treatment are not as high as ex pected

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Antithrombotic treatment is avoided in geriatric population owing to its side effects.
📊
Key Findings & Data:Thus, we aimed to examinecomplication rates related to thrombolytic treatment in geriatric patients with pulmonary thromboembolism (PTE).
💡
Conclusion & Impact:Conclusion: Mortality and complication rates in geriatric patients receiving thrombolytic treatment are not as high as ex pected
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Antithrombotic treatment is avoided in geriatric population owing to its side effects. Thus, we aimed to examinecomplication rates related to thrombolytic treatment in geriatric patients with pulmonary thromboembolism (PTE). Materials and Methods: The study included patients aged >65 years who received thrombolytic treatment for a diagnosisof PTE. Patient files were screened retrospectively to extract data on etiology, clinical risk scores, laboratory values, throm bolytic treatment-related complications, and early mortality development. Results: The study included 68 patients (female: 70.6%; mean age: 77.8 years). The Simplified Pulmonary EmbolismSeverity Index score was high in all patients. Early mortality risk classification at admission was high, medium-high, andmedium-low risk in 64.7%, 23.5%, and 11.8% patients, respectively. In-hospital mortality was 30.9%. The causes of deathwere secondary to PTE in 85.7% patients, respiratory failure in 9.6%, and sepsis in 4.7%. Complication-related mortalitywas not observed. The only independent risk factor for mortality was change in consciousness. Conclusion: Mortality and complication rates in geriatric patients receiving thrombolytic treatment are not as high as ex pected

🔖

Cite This Article

GÜMÜŞ, A., ÖZYURT, S., ÖZÇELİK, N., KARA, B. Y., ŞAHİN, Ü., KARADOĞAN, D. (2022). Is it Worth Using Thrombolytic Therapy in ElderlyPatients with Pulmonary Embolism. Erciyes Medical Journal, Cilt: 43 - Sayı: 5, 433–437. https://ajindex.com/articles/502199

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol 2014; 34: 2363–71
  2. Wendelboe AM, Raskob GE. Global burden of thrombosis: Epidemiologic aspects. Circ Res 2016; 118(9): 1340–7
  3. Keller K, Hobohm L, Ebner M, Kresoja KP, Münzel T, Konstantinides SV, et al. Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. Eur Heart J 2020; 41(4): 522–9
  4. Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost 2010; 8(10): 2105–12
  5. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41(4): 543–603
  6. Stein PD, Matta F. Treatment of unstable pulmonary embolism in the elderly and those with comorbid conditions. Am J Med 2013; 126(4): 304–10 7. Stein PD, Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med 2012; 125(5): 465–70
  7. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, et al; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123(16): 1788–830
  8. Pauley E, Orgel R, Rossi JS, Strassle PD. Age-stratified national trends in pulmonary embolism admissions. Chest 2019; 156(4): 733–42
  9. Kniffin WD Jr, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994; 154(8): 861–6
  10. Tanabe Y, Yamamoto T, Murata T, Mabuchi K, Hara N, Mizuno A, et al. Gender differences among patients with acute pulmonary embolism. Am J Cardiol 2018; 122(6): 1079–84
  11. Ceccarelli E, Masotti L, Barabesi L, Forconi S, Cappelli R. Pulmonary embolism in very